Pritchard KI et al. Final overall survival results, including analysis of patients with triple-negative disease and aged ≥70 years, from the Athena study evaluating first-line bevacizumab-containing therapy for locally recurrent (LR)/metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2010;Abstract P2-16-06.

O’Shaughnessy J et al. Meta-analysis of patients with triple-negative disease from three randomized trials of bevacizumab and first-line chemotherapy as treatment for metastatic breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract P6-12-03.

Von Minckwitz G et al. Neoadjuvant chemotherapy with or without bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). San Antonio Breast Cancer Symposium 2010;Abstract S4-6.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.

Dr Gradishar is Director of Breast Medical Oncology and Professor of Medicine at the Robert H Lurie Comprehensive Cancer Center of Northwestern University’s Feinberg School of Medicine in Chicago, Illinois.